NASDAQ: SPROSpero Therapeutics Inc Stock
$0.73-0.02 (-2.67%)
Updated Apr 21, 2025
SPRO Price
$0.73
Fair Value Price
N/A
Market Cap
$40.53M
52 Week Low
$0.51
52 Week High
$1.72
P/E
-0.57x
P/B
0.88x
P/S
1.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$47.98M
Earnings
-$68.57M
Gross Margin
100%
Operating Margin
-142.91%
Profit Margin
-142.9%
Debt to Equity
1.4
Operating Cash Flow
-$23M
Beta
0.84
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SPRO Overview
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SPRO's potential to beat the market
- SPRO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SPRO
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important SPRO news, forecast changes, insider trades & much more!
SPRO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SPRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPRO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SPRO is good value based on its book value relative to its share price (0.88x), compared to the US Biotechnology industry average (4.04x)
P/B vs Industry Valuation
SPRO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SPRO due diligence checks available for Premium users.
Valuation
SPRO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.57x
Industry
-184.27x
Market
27.14x
SPRO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.88x
Industry
4.04x
SPRO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SPRO's financial health
Profit margin
Revenue
$15.0M
Net Income
-$20.9M
Profit Margin
-138.8%
SPRO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SPRO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$110.5M
Liabilities
$64.4M
Debt to equity
1.4
SPRO's short-term assets ($107.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPRO's short-term assets ($107.28M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPRO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SPRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.4M
Investing
$0.0
Financing
$0.0
SPRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SPRO vs Biotech Stocks
Spero Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.